Hepatitis viral C in kidney transplantation: comparative study between two Maghrebin centers: Casablanca and Tunis

##plugins.themes.academic_pro.article.sidebar##

Published Nov 29, 2010
Download
pdf
Vol. 88 No. 12 (2010): Issue Dec 2010

##plugins.themes.academic_pro.article.main##

Yousr Lakhoua Gorgi
Farah Gorgi
Ghislen Madkouri
Ezzeddine Abderrahim
Imene Sfar
Benyounes Ramadani
Houda Aouadi
Saloua Jendoubi-Ayed
Taieb Ben Abdallah
Khaled Ayed

Abstract

Background: Hepatitis viral C (HVC) is relatively frequent among kidney transplants. It is responsible for a morbi-mortality that compromises the results of transplantation in the medium and long term.
Aim: To evaluate and to compare the prevalence of HVC, 172 kidney transplant adult patients were investigated in two Maghrebian centers at Casablanca (G1): 57 Moroccan patients and Tunisia (G2):.115 Tunisian patients. The impact of the HVC infection for a morbi-mortality was concerned only the Tunisian recipient patients : 20 kidney recipients having antibodies anti-VHC and positive HVC-RNA (Cases) which were matched in age, sex and date of the kidney graft, to 20 kidney transplant patients anti-HVC and VHCRNA negative (Controls).
Methods: The anti-VHC antibodies were detected by ELISA: Innogenetics and their positivity were confirmed by RIBAII. The ARN-VHC was analyzed by RT-PCR INNO-LiPA HCV II amplification of Innogenetics.
Results: The prevalence of hepatitis C is similar for the two groups: 19.3% among Moroccan kidney transplants and 20.9% among Tunisians. The infection by the HVC was often active and the detection of viral RNA was found in 91.7% of the G2 patients against 50% among G1 patients. The genotype 1b is the most prevalent; it is found in 59% of the patients. The frequency of HVC among our kidney transplant patients is particularly determined by the duration and the mode of dialysis. In fact, 22.1% of the patients treated by hemodialysis are VHC (+) against 5,6% patients treated by peritoneal dialysis. Also, the average duration of the dialysis is 58,8 months for HVC (+) patients against 33.5 months for HVC (-) (p<0.0001) patients. The frequency of the chronic rejection of the graft is higher in the G2, but it is similar in Tunisian patients with or without antibodies anti-HVC. In the G1, this frequency is statistically higher among positive HVC transplant patients
compared to the negative HVC grafted patients (p<0.05). The case-control study emphasizes the frequency of the proteinuria, the renal insufficiency, the
mellitensis diabetes and the polyglobulinemia among patients HCV (+); however the differences between the two groups remain statistically non significant. The total rate of the hospitalizations is 26 per 100 patients per year in the HCV (+) group against 17 for the HCV (-). The average duration of hospitalizations is 72 days among HCV (+) patients against 30.2 days for the controls (p<0.05). The averages of survival of the patients and of the controls were similar 11.6 ± 5.6 years for transplant patient HCV (+) against 11.2 ± 5.5 years for the controls. The actuarial curves of the patients were not different for the patients having antibodies anti-HCV positive or negative.
Conclusion: The blood and nosocomial modes of contamination of HVC infection explain their higher frequency in this population at risk. The mortality and the morbidity of the renal transplant patients infected by the HCV seem to be higher compared to the uninfected patients. A further study by large population should be carried out to confirm these results.

Keywords:

hepatitis viral C, hemodialysis, kidney transplantation

##plugins.themes.academic_pro.article.details##

References

  1. Fishman JA, Rubin RH. Infection in organ transplant recipients. Medical Progress 1998; 338: 1741-51.
  2. Rubin RH. Infections disease complications of renal transplantation. Kidney Int 1993; 44: 221-36.
  3. Gane E. Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427-37.
  4. Pol S, Legendre C. Viral hepatitis in hemodialysis and renal transplantation patients. Nephrologie 1994;15:191-5.
  5. Chan TM, Lok ASF, Cheng IKP, Chan RT. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 1993; 104: 862-8.
  6. Favero MS, Alter MJ, Bland LA. Nosocomial infections associated with hemodialysis. In Mayhall, Hospital Epidemiology and Infection Control, 1st edition 1996; 693-714.
  7. Pol S, Debure A, Degott C, et al. Chronic hepatitis in kidney allograft recipients. Lancet 1990; 335: 878-80.
  8. Gallego E, Lopez A, Perez J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006; 104:1-6.
  9. Trépo C, Merle P, Zoulin F. Hépatites virales B et C dans Pathologie Science 2006. Edition: John Libbey.
  10. Pedroso S, Martins L, Fonseca I, et al. Impact of hepatitis C virus on renal transplantation: association with poor survival. Transplant Proc 2006; 38:1890-4
  11. Seth AK, Anand AC, Gedela SP, Baliga KV. Rapid progression of hepatitis C-induced liver failure in renal allograft recipients. Indian J Gastroenterol 2006; 25:155-6.
  12. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677-83.
  13. Carbognin SJ, Solomon NM, Yeo FE, et al. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am J Transplant 2006; 6:1746-51.
  14. Desenclos JC. L'infection par le virus de l'hépatite C dans le monde: importance en santé publique, modes de transmission et perspectives. Virologie 2003; 7: 177-92.
  15. Lindsay KL, El-Shahawy M, Milstein S, et al. HCV RNA levels are lowered during hemodialysis in patients with HCV chronic hepatitis C. Hepatology (abstract) 1994; 20:239A.
  16. Fabrizi F, Lunghi G, Marai P, et al. Virological and histological features of hepatitis C (HCV) infection in kidney transplant recipients. Nephrol Dial Transplant 1996; 11: 159-64.
  17. Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45: 238-44.
  18. Thierry N, Sylvie R, François D. Epidémiologie de l'hépatite C en Afrique. Gastroentérol Clin Biol 1997; 21 :596-606.
  19. Benamar L, Rhou H, Ezzaitouni F, et al. Hépatite virale C chez les hémodialysés chroniques au CHU de Rabat, prevalence et facteurs de risqué. Médecine du Maghreb 2001; 89 :17-20.
  20. Ayed K, Gorgi Y, Ben Abdallah T, et al. Hepatitis C virus infection in hemodialysis patients from Tunisia: national survey by serologic and molecular methods. Transplant Proc 2003; 35: 2573-75.
  21. Cassidy MJD, Jankelson D, Becker M, Moosa R. Hepatitis C and hemodialysis : more evidence for nosocomial spread. International association of nephrology (abstract). Jerusalem 1993; 392.
  22. Dussol B, Berthezene P, Bruet PH, Roubicek C, Berland Y. Hepatitis C among chronique dialysis patients in South of France. Am J of Kidney Diseases 1995; 25: 399-404.
  23. Kuhns M, De Medina M, Mc Namara A, et al. Detection of hepatitis C virus RNA in hemodialysis patients. J Am Soc Nephrol 1994; 4: 1491-97.
  24. Huraib S, Alrasheed R, Aldrees A, Aljefry M, Hrif M, Faieh FA. High prevalence and risk factors for hepatitis C in Saudi Arabia: a need for new strategies in dialysis practice. Nephrol Dial Transplant 1995; 10: 470-74.
  25. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French Consensus. Gut 2003; 52: 1784-7.
  26. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088-96.
  27. Silini E, Bottelli R, Asti M, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A case-control study. Gastroenterology 1996; 111: 199-205.
  28. Romeo R, Tommasini M, Rumi M, et al. Genotypes in the progression of hepatitis C related cirrhosis and development of hepatocellular carcinoma (abstract). Hepatology 1996; 24: 153A:108.
  29. Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T. Hepatitis C virus genotypes are not responsible for development of serious liver diseases. Dig Dis Sci 1994; 39: 234-9.
  30. Cantu P, Mangano S, Masini M, Limido A, Crovetti G, Defilippo C. Prevalence of antibodies against hepatitis C virus in a dialysis unit. Nephron 1992; 61: 337-8.
  31. Cendoroglo-Neto M, Draibe SA, Silva AE et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: Evidence for environnemental transmission. Nephrol Dial Transplant 1995; 10: 240-6.
  32. Huang CC, Wu MS, Lin DY, Liaw YF. The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1992; 12: 31-33.
  33. Selgas R, Martinez-Zapico R, Bajo MA et al. Prevalence of hepatitis C antibodies (HCV) in dialysis population at one center. Perit Dial Int 1992; 12: 28-30.
  34. Knudsen F, Wantzin P, Rasmussen K et al. Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease. Kidney Int 1993; 43: 1353-56.
  35. Pereira B, Levey A. Hepatitis C infection in dialysis and renal transplantation. Kidney Int 1997; 51:981-99.
  36. Casio JM, Campistol JM, Dominguez-Gil B. Hepatitis C virus infection and kidney transplantation. Sem Nephrol 2002; 22: 365- 74.
  37. Delladetsima I, Psichogiou M, Sypsa V, et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective followup study. Am J Kidney Dis. 2006; 47: 309-16.
  38. Corell A, Morales JM, Mandrono A, et al .Immunosuppression induced by hepatitis C virus infection reduces acute renaltransplant rejection. Lancet 1995; 346: 1497-8.
  39. Pascual J, Crespo M, Mateos ML, et al. Reduced severity of acute rejection in hepatitis C virus positive renal allograft recipients: Are milder immunosuppressive regimens advisable? Transplant Proc 1998; 30: 1329-30.
  40. Kamar N, Selves J, Sandres-Saune K, Durand D, Izopet J, Rostaing L. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation? Transplant Proc 2006; 38:1329-32.
  41. Munoz De Bustillo E, Ibarrola C, Colina F et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109-13.
  42. Pol S, Cavalcanti R, Carnot F, et al. Azathioprine hepatitis in kidney transplant recipients: A predisposing role of chronic viral hepatitis. Transplantation 1996; 61: 1774-6.
  43. Zylberberg F, Carnot F, Mamzer MF et al. Hepatitis C virusrelated fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997; 63: 158-60.
  44. Kamar N, Izopet J, Ribes D, Rostaing L. Infection par le virus de l'hépatite C en transplantation rénale. Néphrologie 2004; 25: 9- 15.
  45. Hanafusa T, Ichikawa Y, KishikaWA H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-6.
  46. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Straffon RA. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999; 67: 272-5.